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The Impact of Female Gender on Outcome Following Carotid Revascularisation
G.J. de Borst*, F.L. Moll
Department of Vascular Surgery, G04.129, University Medical Center Utrecht, PO Box 85500, 3508GA Utrecht, The NetherlandsWomen at any age have a lower risk of stroke than men.
However, because women on average live longer than men and the
risk of stroke increases with advancing age, the burden of stroke is
greater in women than in men.1 The recognition of sex differences
has raised awareness of the burden of cardiovascular disease in
women in the last decade, giving further rise to analyses on
intervention-type-speciﬁc outcome differences between sexes.2
In terms of long-term stroke prevention by carotid endarterec-
tomy (CEA), women do not gain equivalent clinical beneﬁt with
respect to men for both symptomatic3 and asymptomatic carotid
stenosis.4 The lower magnitude of beneﬁt in women is most
probably due to a (slightly) higher procedural risk as compared
with men,5 combined with the lower natural history risk of stroke
in women.
Bisdas et al. retrospectively assessed sex-differentiated in-
hospital outcomes following CAS (Carotid Angioplasty with Stent-
ing) or CEA in mainly asymptomatic patients,6 based on discharge
data from the New York state on an impressive nearly 70 000
hospitalisations for carotid intervention over a decade. Asymp-
tomatic men and women showed comparable outcomes after both
procedures. Procedural stroke rates were higher after CAS as
compared to CEA in all sub-groups (but only signiﬁcantly different
in symptomatic women). There was a twofold increase in stroke/
mortality rate in symptomatic women undergoing CAS compared
to those who had CEA, an observation conﬁrmed by others.7 Of
relevance, as stroke after CAS may occur for a relevant part in the
days following revascularisation, the in-hospital analysis per-
formed might signiﬁcantly underestimate the event rate, especially
in the CAS cohort.
Of note, especially in the light of the ongoing CREST (Carotid
Revascularisation Endarterectomy Versus Stenting Trial) contro-
versy, myocardial infarction (MI) showed not to be a main driver of
the composite ‘end’ point independent of presenting neurological
status for both sexes. Asymptomatic womenweremore prone toMI
after both revascularisations than men, a ﬁnding conﬁrmed in
randomised data.8 Unfortunately, no clear deﬁnition of MI other
than a discharge ‘code 410’ in any position could be provided.
Furthermore, and highly surprisingly, no dedicated The Interna-
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Fig. 1). Inﬂuence of hospital annual volume on CAS and CEA
outcomes remained unclear. Within women, only 2074 patients
received CAS, and out of these, only 250 received stenting for
a symptomatic lesion. Over a 10-year time frame, with statewide
discharge data from (e.g.) 25 centres, the CAS experience for
symptomatic lesions could have been only two per centre per year!
The cut-off for hospital CAS volumewas 17 procedures, but this was
clearly reached predominantly by treating asymptomatic patients.
In any case, women have higher perioperative adverse events
(i.e., stroke, combined death/stroke and MI) rates than men. The
authors recommend that “these sex-associated differences should
be taken into account for the treatment of carotid artery disease.”
But how? e for the time being, until data from the ongoing ACST2
(Asymptomatic Carotid Surgery Trial) or SPACE2 (Stent-Protected
Angioplasty versus Carotid Endarterectomy) trials will prove
otherwise, by predominantly treating symptomatic patients, and
offering both men and women CEA as treatment of ﬁrst choice.References
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